OKYO Pharma reported cash from operations of -$5.94M and free cash flow of $6074.06M for the quarter ended Mar 2026, up 37.5% year over year. This cash flow statement covers 10 quarters of results from Mar 2022 through Mar 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Mar2022 | Mar2023 | Sep2023 | Mar2024 | Sep2024 | Dec2024 | Mar2025 | Sep2025 | Dec2025 | Mar2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||
| Share-based Compensation | 1.12M | 0.19M | 0.87M | |||||||
| Gains from Investment Securities | 0.06M | 0.19M | -0.70M | |||||||
| Non-cash Items | 0.04M | -0.04M | ||||||||
| Cash from Operations | -9.49M | -0.28M | -5.94M | |||||||
| Depreciation, Depletion & Amortization | ||||||||||
| Depreciation & Amortization (CF)Depreciation & Amortization | 3,866.00M | 2,563.00M | -743.00M | |||||||
| Change in Working Capital | ||||||||||
| Change in Receivables | 0.44M | 0.09M | 0.10M | |||||||
| Change in Account Payables | 2.80M | 1.86M | -0.85M | |||||||
| Investing Activities | ||||||||||
| Capital Expenditures | -6080.00M | |||||||||
| Change in Acquisitions & Divestments | -6.00M | |||||||||
| Cash from Investing Activities | -6.01M | |||||||||
| Financing Activities | ||||||||||
| Change in Capital Stock | ||||||||||
| Shares Issued | 0.35M | 0.35M | ||||||||
| Net Shares Issued and Repurchased | -0.02M | -0.01M | -1419.00M | -0.09M | -1419.00M | -0.09M | -3070.00M | -0.09M | -3069.00M | |
| Net Equity Issued and Repurchased | 6.21M | -2.61M | 23.32M | |||||||
| Misc. | ||||||||||
| Cash from Financing Activities | 6.21M | -1.66M | 22.37M | |||||||
| Exchange Rate Effect | 0.06M | 0.02M | -0.05M | |||||||
| Change in Cash | -3.28M | -1.95M | 12.24M | |||||||
| Beginning Cash Balance | 4.05M | 4.05M | 0.83M | 0.83M | 1.56M | |||||
| Free Cash Flow | -9.49M | -0.28M | 6,074.06M | |||||||
| Net Cash Flow | -3.28M | -1.94M | 10.43M |